|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CISH |
Gene summary for CISH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CISH | Gene ID | 1154 |
| Gene name | cytokine inducible SH2 containing protein | |
| Gene Alias | BACTS2 | |
| Cytomap | 3p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q9NSE2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1154 | CISH | HCC1_Meng | Human | Liver | HCC | 2.99e-02 | -1.45e-02 | 0.0246 |
| 1154 | CISH | HCC1 | Human | Liver | HCC | 1.80e-04 | 8.13e-01 | 0.5336 |
| 1154 | CISH | S015 | Human | Liver | HCC | 2.44e-03 | 2.98e-01 | 0.2375 |
| 1154 | CISH | S027 | Human | Liver | HCC | 4.42e-06 | 7.66e-01 | 0.2446 |
| 1154 | CISH | S028 | Human | Liver | HCC | 5.16e-16 | 8.12e-01 | 0.2503 |
| 1154 | CISH | S029 | Human | Liver | HCC | 2.57e-13 | 7.41e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| GO:0006661 | Liver | HCC | phosphatidylinositol biosynthetic process | 69/7958 | 131/18723 | 1.19e-02 | 4.35e-02 | 69 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CISH | insertion | Frame_Shift_Ins | novel | c.679dupC | p.Leu227ProfsTer125 | p.L227Pfs*125 | Q9NSE2 | protein_coding | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
| CISH | insertion | Frame_Shift_Ins | novel | c.649_650insACCCCCT | p.Pro217HisfsTer137 | p.P217Hfs*137 | Q9NSE2 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CISH | SNV | Missense_Mutation | rs145632110 | c.370C>T | p.Arg124Cys | p.R124C | Q9NSE2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CISH | SNV | Missense_Mutation | c.787N>T | p.Arg263Cys | p.R263C | Q9NSE2 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-AA-3655-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CISH | SNV | Missense_Mutation | c.704N>A | p.Ser235Asn | p.S235N | Q9NSE2 | protein_coding | tolerated(0.48) | benign(0.001) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CISH | SNV | Missense_Mutation | c.273N>A | p.Phe91Leu | p.F91L | Q9NSE2 | protein_coding | tolerated(0.16) | benign(0.419) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CISH | SNV | Missense_Mutation | c.80N>A | p.Pro27His | p.P27H | Q9NSE2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.74) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CISH | SNV | Missense_Mutation | novel | c.52N>G | p.Met18Val | p.M18V | Q9NSE2 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CISH | SNV | Missense_Mutation | rs780805211 | c.466N>T | p.Arg156Cys | p.R156C | Q9NSE2 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CISH | SNV | Missense_Mutation | novel | c.19N>G | p.Ser7Gly | p.S7G | Q9NSE2 | protein_coding | deleterious_low_confidence(0.01) | benign(0.025) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1154 | CISH | NA | EPO | EPOETIN ALFA | 12396724 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |